In summary, liraglutide improves hepatic TH resistance in T2DM with NAFLD, and restoration of impaired TRβ expression in NAFLD may be a potential mechanism involved in the process of liraglutide therapy. The gene discussed is THRB; the disease is type 2 diabetes mellitus.